Effect of valsartan on kidney outcomes in people with impaired glucose tolerance

Aims To examine the effect of valsartan on kidney outcomes in patients with impaired glucose tolerance ( IGT ). Methods In a double‐blind randomized trial, 9306 patients with IGT were assigned to valsartan (160 mg daily) or placebo. The co‐primary endpoints were the development of diabetes and two composite cardiovascular outcomes. Prespecified renal endpoints included: the composite of renal death, end‐stage renal disease ( ESRD ) or doubling...